This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Pyruvate kinase M2 isozyme (PKM2)	<p>Mouse and cell culture studies suggest PKM2 activators could block an antioxidant mechanism to help treat cancer. In human lung cancer cell lines, a small molecule PKM2 activator increased oxidative stress-induced cell death compared with vehicle. Next steps could include testing PKM2 activators in models of cancer with high levels of oxidative stress.</p> <p>Agios Pharmaceuticals Inc. has a discovery program targeting PKM2 to treat cancer.</p> <p>Dynamix Pharmaceuticals Ltd.'s DNX-3000, a fructose bisphosphate mimetic that activates PKM2, is in preclinical development to treat cancer.</p> <p>SciBX 4(45); doi:10.1038/scibx.2011.1263 Published online Nov. 17, 2011</p>	Patent and licensing status unavailable	<p>Anastasiou, D. <i>et al. Science</i>; published online Nov. 3, 2011; doi:10.1126/science.1211485</p> <p>Contact: Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, Mass.</p> <p>e-mail: lewis_cantley@hms.harvard.edu</p>